Effect of Ojomehantak Tablet and Mustadi Ghanavati in Type 2 Diabetes Mellitus with Secondary Failure to Oral Hypoglycemic Agents: An Open-Label Case Series
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder frequently associated with secondary failure to oral hypoglycemic agents (OHA), leading to inadequate glycemic control and increased risk of complications. Ayurveda correlates T2DM with Prameha, characterized by Kapha predominance, Meda dushti, and impaired Agni. The present study evaluated the effect of Ojomehantak tablet and Mustadi Ghanavati in patients with T2DM exhibiting secondary failure to OHA.
Materials and Methods: An open-label clinical case series was conducted in 10 patients aged 30–65 years with documented secondary failure to OHA. Participants received Ojomehantak tablet (500 mg twice daily) and Mustadi Ghanavati (500 mg twice daily) for 3 months. Assessment included objective parameters (fasting blood sugar, postprandial blood sugar, and glycated hemoglobin [HbA1c]) and subjective symptom grading based on classical features of Prameha. Paired t-test was used for normally distributed biochemical data, and the Wilcoxon signed-rank test for ordinal symptom scores.
Results: Significant reductions were observed in fasting blood glucose (211.79 ± 32.28 to 111.42 ± 18.82 mg/dL; P < 0.001), post-prandial glucose (263.81 ± 36.90 to 146.24 ± 16.73 mg/dL; P < 0.001), and HbA1c (7.86 ± 1.00% to 5.60 ± 0.46%; P < 0.001). Total subjective symptom score significantly decreased (16.8 ± 2.3 to 5.4 ± 1.6; P < 0.005) with a large clinical effect size (r = 0.89). No adverse effects were reported during the study period.
Conclusion: The combination of Ojomehantak tablet and Mustadi Ghanavati demonstrated statistically and clinically significant improvement in glycemic control and symptomatic relief in patients with T2DM and secondary OHA failure. These preliminary findings support further large-scale randomized controlled trials to validate efficacy and safety.
References
1. World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016.
2. International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels: International Diabetes Federation; 2021.
3. Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India. Health Adm. 2009;22(1-2):1-18.
4. American Diabetes Association. Classification and diagnosis of diabetes mellitus. Diabetes Care. 2022;45 Suppl 1:S17-38.
5. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787-835, ix.
6. Powers AC, Stafford JM, Rickels MR. Diabetes mellitus: Complications. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s principles of internal medicine. 21st ed. New York: McGraw-Hill; 2022. p. 2850-75.
7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA. 1999;281(21):2005-12.
8. Sharma RK, Dash B. Chikitsasthana; prameha chikitsa adhyaya. In: Charaka samhita (text with English translation and critical exposition). Vol. 3. Varanasi: Chaukhambha Sanskrit Series Office; 2018.
9. Tripathi B. Nidanasthana; prameha nidana adhyaya. In: Ashtanga hridaya with nirmala hindi commentary. Varanasi: Chaukhambha Sanskrit Pratishthan; 2019.
10. Acharya YT. Nidanasthana; prameha adhyaya. In: Sushruta samhita with nibandha sangraha commentary. Varanasi: Chaukhambha Orientalia; 2017. 11. Daundkar A, Sawant P, Avhad G. Therapeutic applications and ayurveda review on Mustadi Kwath. Int J AYUSH. 2021;10(5):181-6.
12. Utami AR, Maksum IP, Deawati Y. Berberine and its study as an antidiabetic compound. Biology (Basel). 2023;12(7):973. doi: 10.3390/biology12070973
13. Arya G, Pandey P, Tewari P. A review-effect of Mustadi Kwath in madhumeha. World J Pharm Res. 2021;10(10):105-9. doi: 10.20959/ wjpr202110-21103
14. Lekshmi PC, Arimboor R, Nisha VM, Menon AN, Raghu KG. In vitro antidiabetic and inhibitory potential of turmeric (Curcuma longa L) rhizome against cellular and LDL oxidation and angiotensin converting enzyme. J Food Sci Technol. 2014;51(12):3910-7.
15. NIScPR (National Institute of Science Communication and Policy Research). Clinical study on ayurvedic herbal drug (Mustadi Kwatha Ghanavati) therapy in T2DM. New Delhi: National Institute of Science Communication and Policy Research; 2017.
